Indivior Announces $175 Million Accelerated Share Repurchase

Indivior (Nasdaq: INDV) announced a $175 million accelerated share repurchase (ASR) with Barclays under its existing $400 million buyback program on May 4, 2026.

Rhea-AI Summary

Indivior (Nasdaq: INDV) announced a $175 million accelerated share repurchase (ASR) with Barclays under its existing $400 million buyback program on May 4, 2026. Indivior will pay $175 million upfront and expects an initial delivery of 3,717,473 shares, with final settlement tied to VWAP less a discount by end of June 2026. The company said the ASR is not expected to affect its previously issued financial guidance and that up to $100 million of the authorization remains available for future repurchases.

Positive

• Upfront payment of $175 million for the ASR
• Initial delivery of 3,717,473 shares promptly after execution
• ASR executed under existing $400 million repurchase authorization
• Company does not expect the ASR to impact prior financial guidance

Negative

• Upfront $175 million cash outflow reduces available liquidity near term
• Final repurchased share count is uncertain until VWAP-based settlement
• ASR pricing uses VWAP less a discount, which may change final share quantity

Argus May 4 session

+3.51% close to close Open Argus

Details

News Market Reaction – INDV

On May 4, the day this news came out, INDV closed 3.51% above the previous close.

Data tracked by StockTitan Argus for the May 4 session.

Key Figures

ASR size: $175 million Repurchase authorization: $400 million Remaining authorization: $100 million +5 more

ASR size

$175 million

Accelerated share repurchase with Barclays under existing program

Repurchase authorization

$400 million

Total share repurchase program authorized by Board

Remaining authorization

$100 million

Capacity left after the $175M ASR and prior activity

Initial shares delivered

3,717,473 shares

Initial delivery expected promptly after ASR execution

Upfront ASR payment

$175 million

Paid to Barclays at ASR commencement

ASR final settlement

End of June 2026

Expected latest date for final ASR settlement

Company history

25+ years

Time focused on addiction treatment and opioid use disorder

Existing program capacity

$400 million

ASR executed under previously authorized program

Previous Buybacks Reports

1 past event · Latest: Jul 25

Same Type 1 event

1. Jul 25

   Share repurchase plan

   24h Move

   +20.3%

   New $100 million share repurchase program over accelerated six-month window.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

accelerated share repurchase, volume weighted average price, opioid use disorder, forward-looking statements, +2 more

6 terms

accelerated share repurchase financial

"entered into a $175 million accelerated share repurchase agreement"

An accelerated share repurchase is a deal where a company hires a bank to buy back a large block of its own stock immediately on the open market, with the bank later settling the exact number of shares over time. For investors it matters because the immediate reduction in shares outstanding can raise per‑share earnings and often supports the stock price, but it also uses company cash or borrowing and can change liquidity and future growth funding.

volume weighted average price technical

"based on the volume weighted average price of Indivior’s common stock"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

opioid use disorder medical

"treatments for opioid use disorder (OUD), Indivior is singularly focused"

Opioid use disorder is a medical condition where a person repeatedly seeks and uses opioid drugs despite harmful physical, social or mental effects, often involving strong cravings and withdrawal symptoms when stopping. It matters to investors because its prevalence, availability of effective treatments, regulatory responses, and legal or insurance costs can shift demand, revenue and risk across drug makers, treatment providers and insurers—like a widespread problem that reshapes an entire market.

forward-looking statements regulatory

"Important Cautionary Statement Regarding Forward-Looking Statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

capital allocation financial

"commitment to disciplined capital allocation."

Capital allocation is the process of deciding how a company or individual uses their money to grow, pay bills, save, or invest. It matters because good decisions can help build wealth and ensure resources are used wisely, while poor choices can limit growth or cause financial problems. Think of it like managing your allowance—deciding whether to spend, save, or invest to meet your goals.

View in glossary

medication-for-opioid-use-disorder (MOUD) medical

"reduce medication-for-opioid-use-disorder (MOUD) diversion"

Medications for opioid use disorder (MOUD) are prescription drugs that reduce cravings and withdrawal symptoms for people addicted to opioids, acting like a controlled safety net that helps stabilize daily life and lower the risk of overdose. Investors care because MOUD drives demand for specific therapies, is influenced by regulation, reimbursement and treatment capacity, and can materially affect revenue and growth for companies making, distributing or supporting these treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”). The ASR will be executed under Indivior’s existing $400 million share repurchase program previously authorized by the Company’s Board of Directors. The ASR reflects the Company’s confidence in its long-term strategy, cash flow generation, and commitment to disciplined capital allocation.

Under the ASR agreement, Indivior will make an upfront payment of $175 million to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly following execution. The final number of shares repurchased will be determined based on the volume weighted average price of Indivior’s common stock during the term of the ASR, less a discount. Final settlement is expected to occur no later than the end of June 2026. Indivior does not expect the ASR to impact its previously issued financial guidance.

The remaining $100 million under the share repurchase authorization may be used for additional repurchases from time to time, subject to market conditions and other factors. Repurchases may be made through open market transactions, privately negotiated transactions, or other methods permitted under applicable law.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

Important Cautionary Statement Regarding Forward-Looking Statements

This announcement contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding expected share repurchases, our long-term strategy, cash flow generation, commitment to disciplined capital allocation, and other statements containing the words "believe," "anticipate," "plan," "expect," "intend," "estimate," "forecast," “strategy,” “target,” “guidance,” “outlook,” “potential,” "project," "priority," "may," "will," "should," "would," "could," "can," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including: cash available for share repurchases in the future, and the market price of our common stock in the future. For additional information about some of the risks and important factors that could affect our future results and financial condition, see "Risk Factors" in our Annual Report on Form 10-K filed February 26, 2026, and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

For Further Information

Investors	Jason Thompson	VP, Investor Relations	+1 804 402 7123 jason.thompson@indivior.com
Media	Cassie France-Kelly	VP, Communications	+1 804 594 0836 Indiviormediacontacts@indivior.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What exactly did Indivior (INDV) announce on May 4, 2026 about share repurchases?

Indivior announced a $175 million accelerated share repurchase with Barclays. According to Indivior, the ASR is part of its existing $400 million program and includes an initial delivery of 3,717,473 shares with final settlement by end of June 2026.

How many Indivior (INDV) shares will be repurchased immediately under the May 4, 2026 ASR?

Indivior expects an initial delivery of 3,717,473 shares promptly after ASR execution. According to Indivior, the final number will be adjusted based on the VWAP during the ASR term, less a discount, at settlement.

Will the $175 million ASR affect Indivior's (INDV) financial guidance for 2026?

Indivior said the ASR is not expected to impact its previously issued financial guidance. According to Indivior, management believes the repurchase is consistent with its cash flow generation and capital-allocation plan.

When will the Indivior (INDV) ASR with Barclays settle and how is the final share count determined?

Final settlement is expected no later than end of June 2026. According to Indivior, the final repurchased share count will be determined by the volume-weighted average price (VWAP) of common stock during the ASR term, less a discount.

How much of Indivior's (INDV) $400 million buyback authorization remains after the $175 million ASR?

After the ASR, $100 million remains available under the company’s authorization. According to Indivior, the remaining amount may be used for additional repurchases subject to market conditions and other factors.